TN2013000358A1 - Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects - Google Patents
Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjectsInfo
- Publication number
- TN2013000358A1 TN2013000358A1 TNP2013000358A TN2013000358A TN2013000358A1 TN 2013000358 A1 TN2013000358 A1 TN 2013000358A1 TN P2013000358 A TNP2013000358 A TN P2013000358A TN 2013000358 A TN2013000358 A TN 2013000358A TN 2013000358 A1 TN2013000358 A1 TN 2013000358A1
- Authority
- TN
- Tunisia
- Prior art keywords
- biomarkers
- fgfr
- subject
- breast cancer
- ligands
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title abstract 4
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title abstract 2
- 229940125830 FGFR1 inhibitor Drugs 0.000 abstract 3
- 108091008794 FGF receptors Proteins 0.000 abstract 2
- 230000003321 amplification Effects 0.000 abstract 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 2
- 238000004393 prognosis Methods 0.000 abstract 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 abstract 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 abstract 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 abstract 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 abstract 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 abstract 1
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 abstract 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161453723P | 2011-03-17 | 2011-03-17 | |
| PCT/US2012/029205 WO2012125812A1 (fr) | 2011-03-17 | 2012-03-15 | Fgfr et ses ligands utilisés comme biomarqueurs du cancer du sein chez des sujets rh positifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000358A1 true TN2013000358A1 (en) | 2015-01-20 |
Family
ID=45888500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000358A TN2013000358A1 (en) | 2011-03-17 | 2013-09-05 | Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130345234A1 (fr) |
| EP (1) | EP2686442A1 (fr) |
| JP (1) | JP2014513930A (fr) |
| KR (1) | KR20140012137A (fr) |
| CN (1) | CN103429759A (fr) |
| AU (1) | AU2012229107A1 (fr) |
| CA (1) | CA2829988A1 (fr) |
| MA (1) | MA34966B1 (fr) |
| MX (1) | MX2013010581A (fr) |
| PH (1) | PH12013501878A1 (fr) |
| RU (1) | RU2013146242A (fr) |
| SG (1) | SG192962A1 (fr) |
| TN (1) | TN2013000358A1 (fr) |
| WO (1) | WO2012125812A1 (fr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7678890B2 (en) | 2005-07-22 | 2010-03-16 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| BRPI0916904A2 (pt) | 2008-08-04 | 2016-10-11 | Fiveprime Therapeutics Inc | polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos |
| AU2010319327B2 (en) | 2009-11-13 | 2015-08-13 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CN104531812A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HUE057725T2 (hu) | 2011-10-03 | 2022-06-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása |
| US10016484B2 (en) | 2011-11-14 | 2018-07-10 | Five Prime Therapeutics, Inc. | Methods of treating lung cancer |
| LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
| CN104144946A (zh) | 2011-12-19 | 2014-11-12 | 爱克索马美国有限责任公司 | 治疗痤疮的方法 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243954A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| EP3052106A4 (fr) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
| AU2014329452B2 (en) | 2013-10-03 | 2019-06-20 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CN105828878A (zh) | 2013-10-28 | 2016-08-03 | 恩格姆生物制药公司 | 癌症模型及相关方法 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CA3082794A1 (fr) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals Inc. | Methodes de traitement de troubles associes aux acides biliaires |
| CN106995368B (zh) * | 2017-01-23 | 2020-12-04 | 温州医科大学 | 一种非atp竞争性fgfr1抑制剂及其应用 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| KR20210018264A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| CN109722480B (zh) * | 2018-05-17 | 2022-04-26 | 上海交通大学 | 一种非小细胞肺癌检测试剂盒及其应用 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (fr) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| WO2021067374A1 (fr) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| PE20221085A1 (es) | 2019-10-14 | 2022-07-05 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
| WO2021076728A1 (fr) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| EP4069696A1 (fr) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| WO2021146424A1 (fr) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1066517B1 (fr) * | 1998-02-25 | 2006-11-29 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Arrangements cellulaires permettant une definition de profil moleculaire rapide |
| SK287181B6 (sk) | 2000-09-11 | 2010-02-08 | Novartis Vaccines & Diagnostics, Inc. | Chinolinónový derivát a jeho použitie a farmaceutický prostriedok s obsahom tohto derivátu |
| US7470709B2 (en) | 2002-08-23 | 2008-12-30 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
| WO2006127926A2 (fr) | 2005-05-23 | 2006-11-30 | Novartis Ag | Formes cristalline et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one |
| US20070218512A1 (en) | 2006-02-28 | 2007-09-20 | Alex Strongin | Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| SG190592A1 (en) * | 2008-04-29 | 2013-06-28 | Novartis Ag | Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods |
-
2012
- 2012-03-15 EP EP12710849.6A patent/EP2686442A1/fr not_active Withdrawn
- 2012-03-15 CN CN2012800138275A patent/CN103429759A/zh active Pending
- 2012-03-15 JP JP2013558169A patent/JP2014513930A/ja active Pending
- 2012-03-15 RU RU2013146242/10A patent/RU2013146242A/ru not_active Application Discontinuation
- 2012-03-15 AU AU2012229107A patent/AU2012229107A1/en not_active Abandoned
- 2012-03-15 MX MX2013010581A patent/MX2013010581A/es unknown
- 2012-03-15 CA CA2829988A patent/CA2829988A1/fr not_active Abandoned
- 2012-03-15 WO PCT/US2012/029205 patent/WO2012125812A1/fr active Application Filing
- 2012-03-15 PH PH1/2013/501878A patent/PH12013501878A1/en unknown
- 2012-03-15 KR KR1020137027000A patent/KR20140012137A/ko not_active Withdrawn
- 2012-03-15 SG SG2013064720A patent/SG192962A1/en unknown
- 2012-03-15 MA MA36245A patent/MA34966B1/fr unknown
- 2012-03-15 US US14/003,312 patent/US20130345234A1/en not_active Abandoned
-
2013
- 2013-09-05 TN TNP2013000358A patent/TN2013000358A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103429759A (zh) | 2013-12-04 |
| SG192962A1 (en) | 2013-09-30 |
| KR20140012137A (ko) | 2014-01-29 |
| MX2013010581A (es) | 2013-10-03 |
| PH12013501878A1 (en) | 2013-10-14 |
| MA34966B1 (fr) | 2014-03-01 |
| RU2013146242A (ru) | 2015-04-27 |
| AU2012229107A1 (en) | 2013-09-19 |
| EP2686442A1 (fr) | 2014-01-22 |
| US20130345234A1 (en) | 2013-12-26 |
| WO2012125812A1 (fr) | 2012-09-20 |
| JP2014513930A (ja) | 2014-06-19 |
| CA2829988A1 (fr) | 2012-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2013000358A1 (en) | Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects | |
| MX361058B (es) | Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero. | |
| MY188938A (en) | Therapeutic, diagnostic and prognostic methods for cancer of the bladder | |
| MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
| MX2020005165A (es) | Biogenesis de miarn en exosomas para diagnostico y terapia. | |
| EA201400117A1 (ru) | Способы и нуклеиновые кислоты для определения прогноза у больных раком | |
| SG10201908277TA (en) | Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas) | |
| NZ612483A (en) | Drug selection for malignant cancer therapy using antibody-based arrays | |
| MY176706A (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
| EP4242329A3 (fr) | Utilisation de marqueurs comprenant de la filamine a dans le diagnostic et le traitement du cancer de la prostate | |
| GB2545361A (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
| GB2519906A (en) | Methods and systems for detecting biological components | |
| WO2013107459A3 (fr) | Micro-arn pour le diagnostic du cancer du pancréas et/ou le pronostic de patients atteints d'un cancer du pancréas au moyen d'échantillons de sang | |
| MX342735B (es) | Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo. | |
| WO2014150751A3 (fr) | Biomarqueurs associés à l'inhibition de brm | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| MX365421B (es) | Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf. | |
| MX2016012697A (es) | Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales. | |
| WO2012017430A3 (fr) | Profils de micro-arn destinés au diagnostic, au pronostic et au traitement d'un mélanome | |
| WO2019094780A3 (fr) | Arn non codant pour la détection du cancer | |
| WO2012059750A3 (fr) | Facteurs | |
| MX2017007656A (es) | Uso de los inhibidores de pan fgfr y metodo para identificacion de pacientes con cancer elegibles para el tratamiento con un inhibidor de pan fgfr. | |
| MY187655A (en) | Use of nucleosome-transcription factor complexes for cancer detection | |
| WO2014071218A3 (fr) | Biomarqueurs pour le cancer du sein et leurs procédés d'utilisation | |
| MX2020006660A (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato. |